Trial Profile
A clinical study of Bucillamine in the potential treatment of COVID-19 in APAC countries
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2020
At a glance
- Drugs Bucillamine (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 08 Apr 2020 According to a Revive Therapeutics media release, company has retained Novotech to serve as the Company CRO to pursue future human clinical studies for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (COVID-19) in Asia-Pacific Countries.
- 01 Apr 2020 New trial record
- 30 Mar 2020 According to an Revive Therapeutics media release, the company seeks to expand the clinical investigation of Bucillamine for COVID-19 in APAC regions, with a particular interest in Japan and South Korea.
Most Recent Events
Trial Overview
Purpose
This study will evaluate Bucillamine in the potential treatment of COVID-19.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
Trial Details
Organisations
- Affiliations Revive Therapeutics
Trial Dates
Other Details
- Design multicentre; prospective
- Phase of Trial Phase II
- Location Asia-Pacific; Japan; South Korea
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| BucillaminePrimary Drug |
-
|
-
|
Bucillamine
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 08 Apr 2020 | Other trial event | According to a Revive Therapeutics media release, company has retained Novotech to serve as the Company CRO to pursue future human clinical studies for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (COVID-19) in Asia-Pacific Countries. Updated 13 Apr 2020 |
| 01 Apr 2020 | New trial record | New trial record Updated 01 Apr 2020 |
| 30 Mar 2020 | Other trial event | According to an Revive Therapeutics media release, the company seeks to expand the clinical investigation of Bucillamine for COVID-19 in APAC regions, with a particular interest in Japan and South Korea. Updated 01 Apr 2020 |
References
-
Revive Therapeutics. Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs. Media-Rel 2020;.
Media Release -
Revive Therapeutics, Novotech. Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG